Systematic Prevention of Further Fractures in Patients With Hip Fractures and Osteoporosis.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2008 by Odense University Hospital.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
National Board of Health, Denmark
University of Southern Denmark
Merck Sharp & Dohme Corp.
Information provided by:
Odense University Hospital
ClinicalTrials.gov Identifier:
NCT00414830
First received: December 21, 2006
Last updated: April 29, 2008
Last verified: April 2008
  Purpose

The purpose of this study is to determine if prevention of further fractures is possible through systematic evaluation for osteoporosis in patients with recent hip fracture


Condition
Hip Fracture
Osteoporosis

Study Type: Observational
Study Design: Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Odense University Hospital:

Estimated Enrollment: 600
Study Start Date: January 2005
Estimated Study Completion Date: September 2009
Detailed Description:

Osteoporosis is a common disease characterized by an increased risk of fracture. Furthermore recent studies has revealed that patients with fractures have increased risk of renewed fracture. Most fractures in the elderly are partly attributable to osteoporosis. The most severe of these shown to be the hip fracture (HFx) which increase mortality and decrease health related quality of life and has major impact on the level of national health service. Solid evidence is available showing several interventions to reduce the risk of osteoporotic fractures. In spite of this only few HFx patients are offered examination or treatment for osteoporosis and very rare this happens on a routine basis.

In the county of Funen and Ribe in Denmark the departments of Endocrinology and Orthopedic Surgery at Odense University Hospital and Hospital of South Western Jutland therefore initiated a fracture discharge program as part of a health technology assessment (HTA) study offering evaluation for osteoporosis to HFx patients. Evaluation consists of Duel Energy X-ray Absorptiometry, Instant Vertebral Assessment, a biochemical panel, and clinical assessment followed by specific anti-osteoporotic treatment as appropriate.

The HTA study is designed as a longitudinal cohort study of patients admitted to the participating departments with a low energy HFx. Inclusion started January first 2005 and ends December 31. 2006. After the last inclusion the follow up of the last patient are set to 2 years. In the study period data will be collected on subsequent fractures, epidemiological and demographic factors, questionnaires on quality of life, and register data on mortality, use of medication, and use of health services. The control group consists of patients admitted to any other hospital in the two participating counties who are not given this systematic evaluation for osteoporosis on a routine basis.

The HTA report will provide data to suggest if a systematic offer of evaluation and treatment of osteoporosis in HFx patients:

can reduce further fractures is accepted by the majority of patients can increase the amount of life years by decreasing mortality can increase quality of life by reducing the amount of fractures is cost effective for the health care providers

  Eligibility

Ages Eligible for Study:   45 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • admitted to the department of orthopedic surgery at Odense University Hospital or Hospital of South Western Jutland with a low energy hip fracture

Exclusion Criteria:

  • dementia
  • pathological fracture
  • severe comorbidity
  • not wanting to participate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00414830

Locations
Denmark
Odense University Hospital, Department og Endocrinology
Odense, Denmark, 5000
Sponsors and Collaborators
Odense University Hospital
National Board of Health, Denmark
University of Southern Denmark
Merck Sharp & Dohme Corp.
Investigators
Principal Investigator: Kim T Brixen, M.D.,PH.D. Odense University Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00414830     History of Changes
Other Study ID Numbers: 023
Study First Received: December 21, 2006
Last Updated: April 29, 2008
Health Authority: Denmark: Danish Dataprotection Agency

Keywords provided by Odense University Hospital:
prevention
health technology assessment
population based
fracture

Additional relevant MeSH terms:
Fractures, Bone
Osteoporosis
Hip Fractures
Wounds and Injuries
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Femoral Fractures
Hip Injuries
Leg Injuries

ClinicalTrials.gov processed this record on September 30, 2014